Danette Daniels is Vice President of the Protein Degrader Platform at Foghorn Therapeutics which she joined recently. She was an early leader in the field of targeted protein degradation, pioneering approaches to monitor cellular kinetics of degradation and most recently, co-developing a new PROTAC modality. Prior to joining Foghorn Therapeutic Danette has been R&D Group Leader of Functional Proteomics at Promega Corporation.